Background
Human cytomegalovirus (HCMV) has emerged as a promising vaccine vector given its ability to elicit robust, sustained immune responses and persistent antigen expression. Pre-existing HCMV cellular immunity, which may impact the immunogenicity of CMV-vectored vaccines, is not well characterized across demographic populations.
Methods
We conducted an ancillary analysis using data from eligible phase I/II HIV Vaccine Trials Network (HVTN) protocols that were conducted in different geographic locations and in which a CMV peptide stimulation was used as an assay control for intracellular cytokine staining (ICS) and multi-parameter flow cytometry. Baseline CMV pp65-specific ICS response, quantified as percent of T-cells expressing IFN-g and/or IL-2, was assessed overall, by region, sex, and age group. Magnitudes of positive responders were measured by the same categories. Response rates were compared using Barnard’s Exact test, and magnitudes of response among responders were compared using Wilcoxon rank sum test.
Results
Seven HVTN protocols were identified, yielding 772 unique participants. The median age of participants was 30 years (IQR 24.0-42.2) and 53% were male. The geographic distribution included 364 (47%) participants from the United States (US), 255 (33%) from South Africa, and 153 (20%) from Latin America. The CD4+ and CD8+ T-cell response rates in the overall population were 68% and 71%, respectively. Response rates for CD4+ T-cells were significantly higher in South Africa compared to Latin America (88% vs 79%, p=0.025) and the US (88% vs. 49%, p<0.001). Response rates for CD8+ T-cells were 92% in Latin America, vs. 91% in South Africa, and 49% in the US (p<0.001). By sex, males had significantly higher response rates than females for both CD4+ (72% vs 63%, p=0.005) and CD8+ T-cells (78% vs 64%, p<0.001). There were no significant differences in response rate by age group. Among responders, those in Latin America had significantly higher magnitudes for CD8+ T-cells compared to those in the United States and South Africa (Fig. 1A). However, no significant differences in response magnitude by sex were detected (Fig. 1B).
Conclusions
Prevalence and magnitude of pre-existing HCMV-specific cellular immunity vary by region and sex, with lower response rates in the US and among females. Future studies are needed to determine if baseline T-cell responses affect immunogenicity of CMV-vectored preventive HIV vaccines.
Table or Figure
